GlassScriptPhysician profile
Sara Ann Sosa
NPI 1356794846
$7,157.35
in general payments reported to CMS, 2019-2025
20 companies · $2,611 in 2025
The $2,611 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $658 · 2022: $1,034 · 2023: $1,159 · 2024: $1,696 · 2025: $2,611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,454 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,453.66 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,054.52 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $915.62 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $706.85 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $705.86 | 2021-2025 | Rexulti |
| Alkermes, INC. | $611.35 | 2022-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $539.31 | 2021-2025 | Ingrezza |
| Abbvie INC. | $422.51 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $380.29 | 2022-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $205.53 | 2021-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $100.03 | 2022-2025 | Spravato |
| Idorsia Pharmaceuticals US INC | $88.08 | 2023-2024 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $85.35 | 2025 | Cobenfy |
| Axsome Therapeutics, INC. | $72.98 | 2023-2025 | Auvelity |
| Collegium Pharmaceutical, INC. | $59.66 | 2025 | Jornay Pm |
| Indivior INC. | $48.61 | 2022-2023 | Perseris |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $43.17 | 2023 | Azstarys, Azstarys |
| Ironshore Pharmaceuticals INC. | $39.91 | 2024 | |
| Vanda Pharmaceuticals INC. | $34.12 | 2024-2025 | Fanapt, Hetlioz |
| Tris Pharma INC | $28.04 | 2025 | Dyanavel Xr |
| Acadia Pharmaceuticals INC | $15.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Sosa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.